Parker Hannifin delivered fourth-quarter earnings of $1.78 per diluted share, resulting in full-year earnings of $6.26 per share. Both metrics were below our expectations as sluggish global demand in Parker’s end markets continues to stunt revenue growth. Additionally, the company has struggled to keep margins flat, which amplifies the impact on earnings. For 2014, the…
Tourmaline Oil reported second-quarter results after the market closed on Friday. Despite weatherrelated setbacks, the company still increased production, and has now set the stage to deliver phenomenal growth in the second half of the year. Results for the quarter lined up with expectations. Production averaged 70.1 thousand barrels of oil equivalent per day versus…
Shares of Sunesis Pharmaceuticals, Inc (SNSS) plunged significantly after the company announced that its phase III trial, VALOR, failed to meet its primary endpoint. The randomized, double-blind, placebo-controlled trial (n=711) evaluated the efficacy of Qinprezo (vosaroxin) and cytarabine in patients suffering from first relapsed or refractory acute myeloid leukemia (AML). The trial failed to reach…
Second-quarter profits to common investors at SunTrust Banks rose 35% to $365 million, or $0.68 a diluted share, from $270 million, or $0.50 a diluted share, a year earlier. Net interest income fell 5% to about $1.2 billion, as reported net interest margin fell to 3.25% from 3.39% in 2012’s second quarter. However, SunTrust’s earnings…
Capital One Financial Corporation reported net income of $1.1 billion or $1.87 per diluted share in the second quarter of 2013, compared with $1.0 billion or $1.79 per diluted share last quarter, and $92 million in second-quarter 2012. Last year’s results reflected significant purchase accounting impacts as Capital One closed the acquisition of HSBC U.S….
The oft-trodden path for a startup biotech is to aim for either a buyout or an IPO—or at minimum, a partnership with a big pharmaceutical company—before dealing with the hefty price tag of a Phase 3 study. One local biotech, however, took on the risk of bucking that trend—and succeeded. That story and much more…
